Experts will convene at the third Miami Cancer Institute Summit of Americas on Immunotherapies for Hematologic Malignancies in January 2022 to discuss advances in immunologically and molecular based system therapies, new-targeted diagnostic and therapeutic strategies for lymphoma, myeloma, and leukemia, the role and timing of hematopoietic cell transplantation, and the latest on CAR T-cell therapies.
Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard immunotherapies for cancer. Two research teams, working collaboratively but using distinct approaches, found that “first-responder” immune cells known as myeloid cells can be manipulated to enhance the activity of tumor-killing T cells.
